The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART

@article{vanLeth2005TheEO,
  title={The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART},
  author={Frank van Leth and S Andrews and Beatriz Grinsztejn and Edmund G. L. Wilkins and M K Lazanas and Joep M. A. Lange and Julio S. G. Montaner},
  journal={AIDS},
  year={2005},
  volume={19},
  pages={463–471}
}
Backgound:A substantial number of patients start their first-line antiretroviral therapy at an advanced stage of an HIV-1 infection. Potential differences between specific drug regimens in antiviral efficacy and safety in these patients are of major importance. Methods:A post-hoc analysis within the randomized controlled 2NN trial comparing efficacy between regimes containing nevirapine (NVP), efavirenz (EFV), or both, in addition to stavudine and lamivudine. Primary outcome: risk of virologic… Expand
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
TLDR
GPO-vir was well tolerated and effective in increasing CD4 cell count and suppressing plasma viremia in advanced HIV infection during the 48 weeks follow-up period. Expand
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
TLDR
In ARV-naive HIV-1-infected patients, the once-daily lamivudine, tenofovirDF and nevirapine regimen resulted in a high rate of early virological failures and the steering committee decided to stop the trial at 12 months. Expand
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
TLDR
The potency of efavirenz-containing regimens across a spectrum of pretreatment VLs and CD4 counts is demonstrated and the risk of virologic failure was not significantly different among subgroups categorized according to pret treatment VL or CD4 count. Expand
Potential Implications of Baseline Viral Load on the Relative Potency of First-line, NNRTI-Based Antiretroviral Therapy
TLDR
For some antiretroviral therapies, patient baseline viral load (VL) has been predictive of relative potency in terms of the regimen achieving sustained virologic suppression, but differences vary according to the study drug, as this trend has not been observed universally. Expand
EFFECT OF BASELINE CD 4 CELL COUNT ON EFFICACY OF HIGHLY-ACTIVE ANTIRETROVIRAL THERAPY FOR HIV PATIENTS RUNNING HEAD : BASELINE CD 4 CELL COUNT TO INITIATE HAART
Background: Comparison of transition rates between CD4 cell count states for individuals starting HAART at different baseline CD4 cell counts controlling for gender, age and drug abuse. Methods:Expand
Long-Term Efficacy of Nevirapine Plus Co-Formulated Abacavir/ Lamividune as Simplification Therapy in HIV-Infected Patients with Undetectable Viral Load
TLDR
The combination of NVP+ABC+3TC is a safe option for maintaining longterm viral suppression and immunological control, preserving renal function and improving hypertriglyceridemia. Expand
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)
TLDR
DRV/r plus RAL was effective and well tolerated in most patients, but virologic failure and integrase resistance were common, particularly in patients with baseline viral load more than 100 000 copies/ml. Expand
The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals
Objectives:We wished to determine the efficacy of nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens in antiretroviral-naive patients commencing highly active antiretroviral therapyExpand
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis
TLDR
Etravirine plus an optimized background significantly reduced HIV-1-RNA levels from baseline after 24 weeks in patients with substantial NNRTI and PI resistance, and demonstrated a favorable safety profile compared with control. Expand
Should HIV therapy be started at a CD4 cell count above 350 cells/μl in asymptomatic HIV-1-infected patients?
TLDR
Given the strong potential for confounding in observational studies and the lack of adjustment for lead-time bias in many analyses, it is not possible to rule out possible long-term detrimental effects of earlier use of HAART until the results from fully powered randomized trials that directly address this issue become available. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Efficacy of Nevirapine-Based HAART in HIV-1-Infected, Treatment-Naive Persons with High and Low Baseline Viral Loads
TLDR
Baseline viral load does not affect virologic outcome in HIV-1-infected, antiretroviral-naive participants treated with nevirapine-containing, PI-sparing HAART. Expand
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
TLDR
The triple nucleoside regimen utilized may be less likely to result in viral suppression to < 50 copies/ml, while the nevirapine-based regimen is associated with a lower increase in CD4 T lymphocytes. Expand
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study
TLDR
There was no clear immunological or virological advantage in starting HAART at a CD4 cell count > 350 rather than at 200–350 × 106 cells/l, and the increase in CD4 cells restored by HAART is meaningful in that they are associated with reduced risk of disease/death. Expand
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
TLDR
Lower CD4 cell counts and higher viral loads at baseline were not associated with poorer virological outcome of ART, and those with baseline viral loads of greater than 100 000 copies/mL had a slower rate of achieving viral suppression. Expand
Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
TLDR
EFV-containing antiretroviral regimens were associated with superior clinical outcome, as measured by time to treatment failure, which is commensurate with other large cohort studies comparing EFV and NVP. Expand
SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals
TLDR
NVP and EFV along with two NRTIs may be equally well tolerated and effective at achieving <50 HIV RNA copies/mL in naive patients with CD4 counts >100 cells/mm3 and HIV RNA <105 copies/ mL. Expand
The Virgo Study: Nevirapine, Didanosine and Stavudine Combination Therapy in Antiretroviral-Naive HIV-1-Infected Adults
TLDR
Combination therapy with the three reverse transcriptase (RT) inhibitors stavudine, once-daily didanosine and either once- or twice-daily nevirapine could be considered as an alternative option for first-line antiretroviral therapy. Expand
VIROLOGICAL SUPPRESSION AT 6 MONTHS IS RELATED TO CHOICE OF INITIAL REGIMEN IN ANTIRETROVIRAL-NAÏVE PATIENTS: A COHORT STUDY
TLDR
A better initial virological response for efavirenz is suggested for treatment-naive patients initiating highly active antiretroviral therapy compared to either nevirapine or the PI, and clinical trial data is required to confirm these findings. Expand
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
TLDR
Antiretroviral therapy with nevirapine or efavirenz showed similar efficacy, so triple-drug regimens with either NNRTI are valid for first-line treatment, there are, however, differences in safety profiles. Expand
Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides
TLDR
Late increases in CD4 cell counts, mostly owing to newly produced cells rather than redistribution, are more pronounced in therapy using a PI, especially in subjects with lower initial CD 4 cell counts. Expand
...
1
2
3
4
...